4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeeking Alpha • 11/14/26
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/13/26
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewsWire • 11/12/26
4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptSeeking Alpha • 11/11/26
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/02/26
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene TherapyMarketBeat • 10/22/26
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial UnderwaySeeking Alpha • 09/29/26
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DMEGlobeNewsWire • 09/28/26
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/17/26
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/13/26
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewsWire • 08/13/26
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion OpportunitySeeking Alpha • 07/20/26
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationGlobeNewsWire • 07/18/26
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina SpecialistsGlobeNewsWire • 06/30/26
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalGlobeNewsWire • 06/29/26
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDGlobeNewsWire • 06/29/26
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?Zacks Investment Research • 06/23/26
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/05/26